ArticleMolecular cancer therapeutics2014
Cancer-associated CD43 glycoforms as target of immunotherapy.
Article in Molecular cancer therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 32 citations in OpenAlex.
- UMG1 Defines a Targetable Subset of T-Cell Lymphomas and Enables Precision Immunotherapy With a First-in-Class CD3ε Bispecific Engager.Hematological oncology · 2026Article
- Next-generation CAR-T therapy for acute myeloid leukemia: bridging innovation with clinical translation.Annals of hematology · 2026Review
- Glucose metabolism in B cell malignancies: a focus on glycolysis branching pathways.Molecular oncology · 2024Review
- Cancer-specific glycosylation of CD13 impacts its detection and activity in preclinical cancer tissues.iScience · 2023Article
- Targeting CD43 optimizes cancer immunotherapy through reinvigorating antitumor immune response in colorectal cancer.Cellular oncology (Dordrecht, Netherlands) · 2023Article
- A spoonful of L-fucose-an efficient therapy for GFUS-CDG, a new glycosylation disorder.EMBO molecular medicine · 2021Article
- Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.Cancer immunology, immunotherapy : CII · 2021Article
- Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Metabolites Profiling of Melanoma Interstitial Fluids Reveals Uridine Diphosphate as Potent Immune Modulator Capable of Limiting Tumor Growth.Frontiers in cell and developmental biology · 2021Article
- Siglec Signaling in the Tumor Microenvironment.Frontiers in immunology · 2021Review
- Roles of Proteoglycans and Glycosaminoglycans in Cancer Development and Progression.International journal of molecular sciences · 2020Review
- Phage Display-Based Nanotechnology Applications in Cancer Immunotherapy.Molecules (Basel, Switzerland) · 2020Review
- Don't sugarcoat it: How glycocalyx composition influences cancer progression.The Journal of cell biology · 2020Review
- Unconventional secretion of α-Crystallin B requires the Autophagic pathway and is controlled by phosphorylation of its serine 59 residue.Scientific reports · 2019Article
- Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia.Cytometry. Part B, Clinical cytometry · 2019Article
- Hexosamine Biosynthetic Pathway and Glycosylation Regulate Cell Migration in Melanoma Cells.Frontiers in oncology · 2019Article
- Revisiting Bacterial Ubiquitin Ligase Effectors: Weapons for Host Exploitation.International journal of molecular sciences · 2018Review
- Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma.Cancer medicine · 2018Article
- Monitoring multiple myeloma by idiotype-specific peptide binders of tumor-derived exosomes.Molecular cancer · 2017Article
- Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice.Blood advances · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 2 countries.
Funding
Abstract
CD43 is a sialoglycosylated membrane protein that is involved in cell proliferation and differentiation. CD43 glycoforms that are recognized by the UN1 monoclonal antibody (mAb) were expressed in lymphoblastoid T-cell lines and solid tumors, such as breast, colon, gastric, and squamous cell lung carcinomas, while unexpressed in the normal counterparts. The cancer association of UN1/CD43 epitope suggested the possibility to use the UN1 mAb for tumor diagnosis and therapy. In this study, we show that the UN1 mAb was endowed with antitumor activity in vivo because its passive transfer inhibited the growth of UN1-positive HPB-ALL lymphoblastoid T cells in mice. Furthermore, we demonstrate that tumor inhibition was due to UN1 mAb-dependent natural killer-mediated cytotoxicity. By screening a phage-displayed random peptide library, we identified the phagotope 2/165 as a mimotope of the UN1 antigen, as it harbored a peptide sequence that was specifically recognized by the UN1 mAb and inhibited the binding of the UN1 mAb to UN1-positive tumor cells. On the basis of sequence homology with the extracellular region of CD43 (amino acids 64 to 83), the 2/165 peptide sequence was likely mimicking the protein core of the UN1/CD43 epitope. When used as vaccine in mice, the 2/165 phagotope raised antibodies against the UN1/CD43 antigen, indicating that the 2/165 phagotope mimicked the UN1 antigen structure, and could represent a novel immunogen for cancer immunotherapy. These findings support the feasibility of using monoclonal antibodies to identify cancer-associated mimotopes for immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.